Belite Bio, Inc
BLTE
$65.00
-$1.22-1.84%
| Weiss Ratings | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.71 | |||
| Price History | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.03% | |||
| 30-Day Total Return | 16.07% | |||
| 60-Day Total Return | 3.01% | |||
| 90-Day Total Return | -21.51% | |||
| Year to Date Total Return | 0.37% | |||
| 1-Year Total Return | 76.10% | |||
| 2-Year Total Return | 120.04% | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -22.92% | |||
| 52-Week Low % Change | 115.13% | |||
| Price | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $86.53 | |||
| 52-Week Low Price | $31.01 | |||
| 52-Week Low Price (Date) | Apr 17, 2024 | |||
| 52-Week High Price (Date) | Nov 14, 2024 | |||
| Valuation | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 2.12B | |||
| Enterprise Value | 1.98B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.32 | |||
| Earnings Per Share Growth | -74.12% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 14.56 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $65.00 | |||
| Enterprise Value/EBITDA (TTM) | -173.36 | |||
| Enterprise Value/EBIT | -172.73 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 31.46M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 246 6240 | |||
| Address | 12750 High Bluff Drive San Diego, CA 92130 | |||
| Website | www.belitebio.com | |||
| Country | United States | |||
| Year Founded | 2016 | |||
| Profitability | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -- | |||
| Return on Equity | -- | |||
| Income Statement | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -- | |||
| Net Income (TTM) | -- | |||
| Net Income Avl. to Common (TTM) | -- | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -44.49% | |||
| EPS Diluted (TTM) | -- | |||
| EPS Diluted Growth (Q YOY) | -30.01% | |||
| Balance Sheet | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 145.15M | |||
| Cash Per Share (Q) | $4.61 | |||
| Total Current Assets (Q) | 147.07M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 145.82M | |||
| Current Ratio (Q) | 24.310 | |||
| Book Value Per Share (Q) | $4.58 | |||
| Total Assets (Q) | 152.13M | |||
| Total Current Liabilities (Q) | 6.05M | |||
| Total Debt (Q) | 537.00K | |||
| Total Liabilities (Q) | 6.31M | |||
| Total Common Equity (Q) | 145.82M | |||
| Cash Flow | BLTE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -- | |||
| Levered Free Cash Flow (TTM) | -- | |||
| Cash from Operations (TTM) | -- | |||
